Castle Biosciences Reports First Quarter 2026 Results Accessibility Statement Skip Navigation Delivered Q1 2026 revenue of $83.7 millionQ1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025Raising full-year 2026 revenue guidance to $345-355 million from $340-350 millionConference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 6, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through i ...